Cipla has disclosed that the USFDA classified its InvaGen New York plant inspection as Voluntary Action Indicated, closing the regulatory review.

The plant is Unit 3 of InvaGen Pharmaceuticals, located in Central Islip, New York. InvaGen is a wholly owned Cipla subsidiary that manufactures generic drugs for the US market.

The USFDA carried out the inspection between July 13 and July 17, and Cipla learned of the final outcome on August 28. Cipla had actually flagged this inspection to investors much earlier, back on July 18.

This latest filing is essentially a follow-up, updating exchanges once the USFDA finished its review.

Company Secretary Rajendra Chopra signed off on the disclosure, made under Regulation 30 of SEBI’s listing rules, which require companies to report material events promptly.

A quick note on what these classifications actually mean. USFDA inspections typically end in one of three ways.

No Action Indicated is the cleanest result, meaning nothing of concern turned up. Voluntary Action Indicated, which is what happened here, means some observations were made but don’t need formal regulatory follow-up, so it’s on the company to fix them.

Official Action Indicated is the serious one, often leading to warning letters. A VAI outcome is usually considered a manageable result in the pharma industry.

The filings themselves were fairly sparse. While Cipla disclosed that it received just one inspectional observation back in July, it didn’t detail what exactly inspectors found or what the company plans to do to fix it.

InvaGen has been part of Cipla’s US business for years, and this New York facility sits under the USFDA’s routine watch because of the role it plays supplying generics to American consumers.

On the numbers side, Cipla’s revenue for the June quarter stood at Rs 7,119.28 crore, up 2.33% year-on-year, while net profit dropped 39.19% to Rs 789.05 crore over the same stretch.

The future of investing is here!

Tradz by EquityPandit leverages advanced AI technology to provide you with powerful market predictions and actionable stock scans. Download the app today and 10x your trading & investing journey!